ACE OncoCast

Updates on Oncogene-Driven NSCLC from Vienna: Targeting KRAS G12C mutation

August 13, 2022 ACE Oncology Season 4 Episode 2
ACE OncoCast
Updates on Oncogene-Driven NSCLC from Vienna: Targeting KRAS G12C mutation
Show Notes

In this episode, our experts discuss current and new strategies for targeting KRAS G12C mutation. Hear about emerging strategies to enhance activity of current treatment options in this molecular subtype.